The acquisition will accelerate the development and commercialisation of PULMOTREE's Kolibri™ Non-Propellant Liquid Inhaler platform, expanding Aptar Pharma's respiratory drug delivery portfolio and capabilities for complex inhaled therapies, including biologics.
Aptar Pharma has announced the strategic acquisition of PULMOTREE, a Munich-based life science company specialising in pulmonary drug delivery systems designed for targeted delivery to the lungs.